Nogo-A抑制促进卒中恢复的临床前证据:范围综述
多数研究在啮齿类动物中完成,抗Nogo-A抗体最常用,27项研究报告有益效应,提示临床前证据支持Nogo/NgR1抑制促进卒中恢复,有必要开展临床试验评估安全性、可行性与疗效。
要点
- 30项临床前研究中27项报告Nogo/NgR1抑制对卒中恢复有益。
- 抗Nogo-A抗体是最常见干预,用于21项研究。
- 多数研究经中枢直接给药,仅5项测试皮下、静脉或鼻内给药。
核心结论
- 大量临床前证据支持抑制Nogo/NgR1信号可促进卒中恢复。
- 有必要在卒中患者中开展临床试验评估安全性、可行性与疗效。
研究设计与样本
- 范围综述遵循PRISMA-ScR扩展版,检索PubMed并追溯引用。
- 纳入标准为评估药物抑制Nogo/NgR1信号的非人卒中模型且评价感觉运动或功能结局的研究,无年份限制。
- 使用SYRCLE工具进行偏倚风险评估。
主要发现
- 90%的研究在啮齿类动物中完成,仅3项(10%)在非人灵长类中完成。
- 抗Nogo-A抗体是最常见药物干预,用于21项(70%)研究。
- 多数研究将药物直接递送至中枢神经系统(鞘内、脑室内或脑实质内),仅5项研究测试皮下、静脉或鼻内给药。
- 30项研究中27项(90%)报告有益效应。
临床怎么用
- 临床前证据支持Nogo/NgR1抑制作为卒中恢复的潜在治疗靶点。
- 现有证据主要来自啮齿类动物及中枢直接给药,向临床转化需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroke is one of the leading causes of disability worldwide. Although preclinical studies have shown promising results of pharmacotherapies to enhance stroke recovery, no drug has been approved for stroke recovery in patients. In this article, we review the preclinical data of one promising treatment, inhibition of NgR1 (Nogo receptor 1) signaling, for stroke recovery. Our scoping review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis Extension for Scoping Reviews and surveyed the peer-reviewed literature on PubMed and citation searching. Studies were eligible if they evaluated the pharmacological inhibition of Nogo/NgR1 signaling in nonhuman models of stroke assessing sensorimotor or functional outcomes. There were no restrictions in years considered. An assessment of the risk of bias was performed using the Systematic Review center for Laboratory Animal Experimentation tool. Three hundred seventeen articles were screened based on the inclusion criteria. Thirty preclinical studies were included. Most studies (90%) were conducted in rodents, with only 3 studies (10%) completed in nonhuman primates. Anti-Nogo-A antibody was the most common pharmacological intervention, used in 21 (70%) studies. Most preclinical studies delivered the study drug directly into the central nervous system (intrathecal, intraventricular, or intraparenchymal), with far fewer studies (n=5) testing subcutaneous, intravenous, or intranasal administration. Among the 30 studies included, 27 (90%) report a beneficial effect. In conclusion, there is a large body of preclinical evidence to support Nogo/NgR1 inhibition in promoting stroke recovery. A clinical trial to assess the safety, feasibility, and efficacy among patients with stroke is warranted.
引用
- Lima JEE, Rengarajan S, Wahl AS, et al. Preclinical Evidence of Nogo-A Inhibition in Stroke Recovery: A Scoping Review. Stroke. 2025. PMID: 40859844. doi:10.1161/STROKEAHA.124.049361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。